scholarly journals Impact of chronic kidney disease on the short- and long-term outcomes of laparoscopic gastrectomy for gastric cancer patients

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0250997
Author(s):  
Katsunobu Sakurai ◽  
Naoshi Kubo ◽  
Yutaka Tamamori ◽  
Naoki Aomatsu ◽  
Takafumi Nishii ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Chronic Kidney Disease ◽  
Multivariate Analysis ◽  
Kidney Disease ◽  
Anastomotic Leak ◽  
Laparoscopic Gastrectomy ◽  
Long Term Outcomes ◽  
Short And Long Term ◽  
The Impact

Backgrounds This study was undertaken to investigate the impact of coexisting chronic kidney disease (CKD) on short- and long-term outcomes of laparoscopic gastrectomy in patients with gastric cancer (GC). Methods We reviewed the data of 798 patients treated for GC by laparoscopic gastrectomy. All procedures took place between January 2010 and December 2017. Patients were divided into three groups according to their estimated glomerular filtration rate (eGFR): severe CKD group, 44 patients with eGFR < 45 mL/min/1.73 m2; moderate CKD group, 117 patients with 45 ≤ eGFR < 60; control group, 637 patients with eGFR ≥ 60. Results Based on multivariate analysis, severe CKD (eGFR < 45) emerged as an independent predictor of anastomotic leak (Hazard ratio 4.63, 95% confidence interval [CI] 1.62–11.54). The 5-year overall survival (OS) rates by group were 46.3% (severe CKD), 76.6% (moderate CKD), and 81.5% (control). Multivariate analysis likewise identified severe CKD (eGFR < 45) as an independent correlate of poor 5-year OS. The 5-year cancer-specific survival (CSS) rates did not differ significantly by group. Conclusions An eGFR value less than 45 mL/min/1.73 m2 is a useful factor for predicting both anastomotic leak and 5-year OS in GC patients undergoing laparoscopic gastrectomy. Clinical care to improve eGFR should be reinforced before and after gastrectomy for GC patients with severe CKD.

Short-Term and Long-Term Outcomes After Gastrectomy for Gastric Cancer in Patients With Chronic Kidney Disease

2013 ◽  
Vol 38 (6) ◽  
pp. 1453-1460 ◽  
Author(s):  
Sohei Matsumoto ◽  
Tomoyoshi Takayama ◽  
Kohei Wakatsuki ◽  
Tetsuya Tanaka ◽  
Kazuhiro Migita ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Long Term Outcomes ◽  
Short Term

scholarly journals Assessment of long term outcomes after buccal mucosal graft urethroplasty: the impact of chronic kidney disease

2019 ◽  
Vol 45 (5) ◽  
pp. 981-988
Author(s):  
Ajay Aggarwal ◽  
Manoj Kumar ◽  
Siddharth Pandey ◽  
Samarth Agarwal ◽  
Satya Narayan Sankhwar
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Long Term Outcomes ◽  
Buccal Mucosal Graft ◽  
The Impact

scholarly journals The Advances of Laparoscopic Gastrectomy for Gastric Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-12 ◽  
Author(s):  
Yeon-Ju Huh ◽  
Joo-Ho Lee
Keyword(s):  
Gastric Cancer ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Invasive Surgery ◽  
Laparoscopic Gastrectomy ◽  
Minimal Invasive ◽  
Long Term Outcomes ◽  
Short And Long Term

Laparoscopic gastrectomy is evolving. With the increasing expertise and experience of oncologic surgeons in the minimally invasive surgery for gastric cancer, the indication for laparoscopic gastrectomy is expanding to advanced cases. Many studies have demonstrated the benefits of minimally invasive surgery, including reduced risk of surgery-related injury, reduced blood loss, less pain, and earlier recovery. In order to establish concrete evidence for the suitability of minimal invasive surgery for gastric cancer, many multicenter RCTs, comparing the short- and long-term outcomes of laparoscopic versus open surgery, are in progress. Advances in laparoscopic gastrectomy are moving toward increasingly minimally invasive approaches that enable the improvement of the quality of life of patients, without compromising on oncologic safety.

Short- and long-term outcomes following laparoscopic gastrectomy for advanced gastric cancer compared with open gastrectomy.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 369-369
Author(s):  
Kazuaki Shibuya ◽  
Hideki Kawamura ◽  
Yosuke Ohno ◽  
Nobuki Ichikawa ◽  
Tadashi Yoshida ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Laparoscopic Gastrectomy ◽  
Clinical Stage ◽  
Stage Ii ◽  
Open Gastrectomy ◽  
Long Term Outcomes ◽  
Significant Difference ◽  
Short And Long Term

369 Background: To investigate the oncological feasibility and technical safety of laparoscopic gastrectomy with D2 lymphadenectomy for advanced gastric cancer. Methods: 186 advanced gastric cancer patients treated by gastrectomy with D2 lymphadenectomy were eligible for inclusion including those with invasion into the muscularis propria, subserosa, and serosa without involvement of other organs, and stages N0–2 and M0. We retrospectively compared the short- and-long term outcomes between laparoscopic gastrectomy and open gastrectomy. Results: We analyzed short-term outcomes by comparing distal- with total gastrectomy results. We found no significant difference for distal gastrectomy for postoperative morbidity (laparoscopic vs. open: n = 4 (4.6%) vs. n = 1 (3.6%); p= 1.00). We also found no significant difference in postoperative morbidity for total gastrectomy (laparoscopic vs. open: n = 2 (4.0%) vs. n = 1 (4.0%); p= 1.00). No deaths occurred in any group. The entire cohort analysis revealed no statistically significant differences in overall- or recurrence-free survival between the laparoscopic and open groups. For overall survival, there were no significant differences between open and laparoscopic groups for clinical stage II or III ( p= 0.29 and 0.27, respectively), and for pathological stage II or III ( p= 0.88 and 0.86, respectively). For recurrence-free survival, there were no significant differences between open and laparoscopic groups for clinical stage II or III ( p= 0.63 and 0.60, respectively), and for pathological stage II or III (p = 0.98 and 0.72, respectively). Conclusions: Laparscopic gastrectomy for advanced gastric cancer compared favorably with open gastrectomy regarding short- and long-term outcomes. Clinical trial information: 160907.

Sign in / Sign up

Export Citation Format

Share Document